Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

Inclusion Criteria: * Between the ages of 18 and 50 years, inclusive. * Acute symptomatic exacerbation of MS present for great than 24 hours and less than or equal to 7 days at entry with new or worsening symptoms, and with signs referable to the symptoms; in the absence of a fever or active infection. * Diagnosis of a relapsing form of multiple sclerosis before randomization as determined by Poser or McDonald Criteria. * Expanded disability status scale (EDSS) score between 2 and 6.5, inclusive at entry. * Episodes include study neurologist or neuro-ophthalmologist diagnosed: acute optic neuritis, cerebellar, brainstem dysfunction, myelitis, focal cerebral, and/or definitive focal sensory dysfunction. * New objective clinical finding other than a sensory exacerbation, or bowel/bladder signs alone. Sensory deficits alone will not qualify except for optic neuritis. * Subjects may continue on their current immunomodulating therapy (such as interferons or glatiramer acetate) throughout the course of the study. Women who become pregnant after the 5-day treatment of steroids should discontinue immunomodulatory treatment. * Understand and sign written informed consent prior to any testing under this protocol, including screening tests and evaluations that are not considered part of the subject's routine care. Exclusion Criteria: * Any patients treated with systemic corticosteroid use within one month of the index episode at screening. * Prior use of immunosuppressive treatments within 90 days of index episode (mitoxantrone, azathioprine, IVIg) or plasmapheresis. * Any patient who is pregnant or breastfeeding. * Unable to perform the Multiple Sclerosis Functional Composite consisting of: Timed 25-Foot Walk, 9-Hole Peg Test, and Paced Auditory Serial Addition Test (3 second). * Peripheral or cranial neuropathy as sole problem of acute episode. * History of any significant cardiac, gastrointestinal, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude corticosteroid therapy. * Primary Progressive Multiple Sclerosis (PPMS). * Previous participation in this study.